Serum NCAM: a potential new prognostic marker for multiple myeloma [letter]

Ulrich Kaiser(University of Applied Sciences Landshut), B. Auerbach(Philipps University of Marburg), Gabriele Jaques(Netherlands Comprehensive Cancer Organisation), K. Havemann(Philipps University of Marburg)
Blood
February 1, 1994
10.1182/blood.v83.3.871.871
Cited by 17

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
|Annals of Oncology|2006|280
<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
|Blood|2021|170
Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).
|Blood|2009|157